BioCryst Pharma Analyst Price Targets - Benzinga

BioCryst Pharmaceuticals Inc

BCRXNASDAQ

Trade with Public

Trade with Public

$8.19

-0.14-1.74%

最終更新: Oct 1, 12:05 PM

$8.22

-0.11-1.31%

概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

BioCryst Pharma Analyst Price Targets - Benzinga

BioCryst Pharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for BioCryst Pharma (BCRX).

Price Target Range — 12 Quarters

Analyst Consensus — 12 Analysts

3S.Buy

7Buy

2Hold

Consensus RatingBuy# Analysts12Avg. Consensus PT$21Upside to Avg. PT+153.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 30, 2026	JP Morgan	Jessica Fye	PT Raise	Neutral	$12→$13
Sep 10, 2026	RBC Capital	Brian Abrahams	Downgrade	Outperform→Sector Perform	$13→$11
Sep 8, 2026	Needham	Serge Belanger	Maintained	Buy	$16
Aug 6, 2026	RBC Capital	Brian Abrahams	PT Cut	Outperform	$14→$13
Aug 6, 2026	Wedbush	Laura Chico	PT Cut	Outperform	$21→$20
Jul 13, 2026	JP Morgan	Jessica Fye	Reinstates	Neutral	$12
Jul 7, 2026	RBC Capital	Brian Abrahams	PT Raise	Outperform	$13→$14
Jun 30, 2026	HC Wainwright & Co.	Andrew S. Fein	Maintained	Buy	$32
Jun 30, 2026	Cantor Fitzgerald	Steven Seedhouse	PT Raise	Overweight	$27→$29
May 7, 2026	Citizens	Jonathan Wolleben	PT Raise	Market Outperform	$25→$28
May 7, 2026	Wedbush	Laura Chico	PT Cut	Outperform	$22→$21
May 6, 2026	Needham	Serge Belanger	PT Cut	Buy	$18→$16
Jan 30, 2026	RBC Capital	Brian Abrahams	PT Cut	Outperform	$14→$13
Dec 15, 2025	HC Wainwright & Co.	Andrew S. Fein	PT Raise	Buy	$30→$32
Nov 5, 2025	Citizens	Jonathan Wolleben	PT Cut	Market Outperform	$27→$25
Nov 4, 2025	Barclays	Gena Wang	PT Cut	Equal-Weight	$11→$9
Nov 4, 2025	Needham	Serge Belanger	PT Cut	Buy	$20→$18
Oct 15, 2025	TD Cowen	Stacy Ku	Reinstates	Buy	$30
Oct 15, 2025	Cantor Fitzgerald	Steven Seedhouse	PT Raise	Overweight	$24→$26
Oct 15, 2025	JMP Securities	Jonathan Wolleben	PT Raise	Market Outperform	$17→$27

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
JP Morgan Maintains Neutral on BioCryst Pharma, Raises Price Target to $13

JP Morgan analyst Jessica Fye maintains BioCryst Pharma (NASDAQ:BCRX) with a Neutral and raises the price target from $12 to $13.

Benzinga Newsdesk

PRO
RBC Capital Downgrades BioCryst Pharma to Sector Perform, Lowers Price Target to $11

RBC Capital analyst Brian Abrahams downgrades BioCryst Pharma (NASDAQ:BCRX) from Outperform to Sector Perform and lowers the price target from $13 to $11.

Benzinga Newsdesk

PRO
Needham Reiterates Buy on BioCryst Pharma, Maintains $16 Price Target

Needham analyst Serge Belanger reiterates BioCryst Pharma (NASDAQ:BCRX) with a Buy and maintains $16 price target.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on BioCryst Pharma, Lowers Price Target to $13

RBC Capital analyst Brian Abrahams maintains BioCryst Pharma (NASDAQ:BCRX) with a Outperform and lowers the price target from $14 to $13.

Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on BioCryst Pharma, Lowers Price Target to $20

Wedbush analyst Laura Chico maintains BioCryst Pharma (NASDAQ:BCRX) with a Outperform and lowers the price target from $21 to $20.

Benzinga Newsdesk

PRO
JP Morgan Reinstates Neutral on BioCryst Pharma, Announces $12 Price Target

JP Morgan analyst Jessica Fye reinstates BioCryst Pharma (NASDAQ:BCRX) with a Neutral and announces $12 price target.

Benzinga Newsdesk